(3.236.122.9) 您好!臺灣時間:2021/05/09 07:13
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

我願授權國圖
: 
twitterline
研究生:張雅玲
研究生(外文):Yea-Ling Chen
論文名稱:緩瀉劑的使用是否影響18F-FDG-PET/CT在腸道系統中的判讀
論文名稱(外文):Application of Laxative in Detection of Colon Lesion by 18F-FDG-PET/CT
指導教授:丘周萍丘周萍引用關係
指導教授(外文):Chou-Ping Chiou
學位類別:碩士
校院名稱:義守大學
系所名稱:醫務管理學系
學門:商業及管理學門
學類:醫管學類
論文種類:學術論文
論文出版年:2016
畢業學年度:104
語文別:中文
論文頁數:85
中文關鍵詞:葡萄糖正子掃描瀉劑大腸癌
外文關鍵詞:FDGPETlaxativescolorectal cancer
相關次數:
  • 被引用被引用:0
  • 點閱點閱:379
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
目的:
癌症是全世界各地方死亡的主要原因其中之一。準確的診斷分期與再分期是癌症病患者的最佳治療管理的環其中一個節,正子斷層造影(Positron Emission Tomography/Copmuted Tomography),以下簡稱PET/CT,但對於正子斷層掃描而言,仍然避免不了偽陽性或偽陰性,腸道的收縮發炎或是平滑肌主動收縮等等,都有可能會大量吸收葡萄糖正子的藥品,所以很容易造成偽陽性,造成影像上的判讀困難,腸道的生理攝取增加,可能會受到便秘與腸道的蠕動與平滑肌的收縮之間的關係與葡萄糖的代謝有關,因此我們想藉由瀉劑的使用,減少因便秘所引起的腸道平滑肌的收縮或蠕動,造成的腸道FDG藥物攝取的增加,以減少腸道生理上的攝取,造成影像上腸道的FDG的攝取造成對於腸道影像的誤判,以利醫師對影像的判斷協助,如果可以在檢查前使用一些方式來降低腸道上影像的偽陽性,協助減少醫師在腸道影像判讀上的難處。
材料與方法:
本研究共計收受共202位,依受檢的次序分成未服用瀉劑與服用瀉劑兩組,未服用瀉劑的人共計109位;服用瀉劑的人共計93位,經由有經驗之核子醫學專科醫師判讀後,依腸道分別統計升結腸、橫結腸、降結腸、乙狀結腸、直腸五段腸道的SUV值,分別統計,1、性別與各腸道SUV值是否有影響,2、年齡與各腸道SUV值間是否有影響,3、其SUV值來判斷未服用瀉劑與服用瀉劑腸道SUV值是否有差異。利用正子掃描的生理功能影像加上電腦斷層提供的人體解剖影像,判讀18F-FDG在人體的代謝分佈,與瀉劑(Klean-prep)的使用,減少因便秘所引起的腸道平滑肌的收縮或蠕動增加所造成的腸道18F-FDG藥物活性攝取的增加,以減少腸道生理上的攝取,由統計軟體SPSS2以描述性統計分析各變項之分布情形。最後以無母數分析Kruskal Wallisru、Mann-Whitney U進行相關檢定。
結果:
採用Mann-Whitney U(P<0.05),檢定其性別是否會干擾影響其各腸道間SUV值的攝取,,發現性別與各腸道間SUV max間,不論是否有使用瀉劑,發現其性別與各腸道間SUV mas間的P value全部皆>0.05,故由此可見,性別並不會干擾其腸道間SUV的攝取,由此可發現年齡並不會影響SUV在腸道影像的判斷;採用Kruskal Wallisru檢定(P<0.05),檢定其年齡是否會干擾影響其各腸道間SUV值的攝取,群組中將其年齡分為三個組別,不論是否有使用瀉劑,發現其年齡與各腸道間SUV mas間的P value全部皆>0.05,故由此可見,年齡並不會干擾其腸道間SUV的攝取,由此可發現年齡並不會影響SUV在腸道影像的判斷;採用Mann-Whitney U檢定(P<0.05),檢定其緩瀉劑的使用是否會干擾影響其各腸道間SUVmax值的攝取,發現瀉劑的使用與各腸道間SUVmax間的P value全部皆<0.05,未使用緩瀉劑的肝臟SUVmax (SUVmax:2.6±0.3)與大腿SUVmax (SUVmax:0.9±0.1)與使用瀉劑後肝臟SUVmax (SUVmax:2.6±0.3)與大腿SUVmax (SUVmax:0.9±0.1)在各組間數值均無特殊變化,故可以了解,瀉劑的使用並不影響其他器官的SUVmax值的攝取。且瀉劑的使用確實可以改善各腸道間SUV值的攝取,SUVmax值的攝取有明顯的下降(P<0.05),由此可證實,瀉劑的使用能使腸道的SUV值下降,減少因腸道的便祕與腸道的蠕動與平滑肌的收縮而造成的SUVmax值升高,而改善腸道的定性影像。

Purpose:
Cancer is the leading cause of death worldwide. Accurate localization of malignant tumor is the important part of treatment planning for the patient of cancer. Fluorine-18- fluorodeoxy glucose (18F-FDG) positron emission tomography/computed tomography (18F-FDG PET/CT) has been proved useful for the detection, staging and restaging of several malignancies. Unfortunately, 18F-FDG PET/CT PET / CT still could not avoid the false positives and false negatives. There are some organs and tissues will have high uptake of 18F-FDG and cause false positive result, such as the inflammatory tissue, genitourinary tract, intestine, muscle, and so on. The reason of intestinal uptake of 18F-FDG may be due to constipation, increased peristalsis of gastrointestinal tract or contraction of intestinal smooth muscle. Therefore, we try to use laxatives to reduce those conditions and hope to decrease intestinal uptake of 18F-FDG. If we can use this method to reduce the intestinal uptake of 18F-FDG and eliminate the false positive of image before examination, it will assist physician to solve the difficulties of image diagnosis.

Materials and Methods:
In this study, we collect 202 subjects to divide into“ not taking laxatives group” and “taking laxatives group”. There are 109 people not taking laxatives and 93 people taking laxatives. Through the physicians of the nuclear medicine who are experienced diagnose. We count the SUV value of colon, descending colon, sigmoid colon and rectum. Then we generalize following three points: 1. Whether the gender will affect the value of each intestinal SUV. 2. Whether the age will affect the value of each intestinal SUV. 3. Whether the taking laxatives will affect the value of each intestinal SUV. The use of positron scanned images plus physiological functions of human anatomy and CT images provided interpretation of 18F-FDG in the body''s metabolic profile, using laxatives (Klean-prep), and reduce shrinkage caused by constipation or intestinal smooth muscle increase intestinal motility caused by 18F-FDG uptake increased pharmaceutically active, in order to reduce the intake of intestinal physiology, the statistical software SPSS2 descriptive statistical analysis of the distribution of the various variables. Finally, we use nonparametric analysis Kruskal Wallisru and Mann-Whitney U to confirm.

Result:
We use Mann-Whitney U (P <0.05) to test whether that gender will affect the uptake of intestinal SUV values. We found between gender and among the various intestinal SUV max all are> 0.05, regardless of whether they have used laxatives. It proves that gender does not interfere with their intestinal uptake between the SUV. It can be found that the age does not affect the reading in the intestinal SUV. We use Kruskal Wallisru test (P <0.05) to judge whether age would be interference between the value of its SUV intestinal uptake. The group is divided into three age groups, regardless of whether they have used laxatives, then we found age and among intestinal P value SUV mas between all are> 0.05. It shows that the age does not interfere with their gut SUV between intake. It can be found that the age does not affect the reading in the intestinal SUV. We use Mann-Whitney U test (P <0.05) to judge whether it would interfere with the use of laxatives affect uptake among its various intestinal SUV max values. We found between the use of laxatives and various intestinal P value SUV max are all <0.05. Unused laxatives liver SUV max (SUV max: 2.6 ± 0.3) and thigh SUV max (SUV max: 0.9 ± 0.1) and liver SUV max (SUV max: 2.6 ± 0.3) after use of laxatives and thigh SUV max (SUV max: 0.9 ± 0.1). There were no specific changes in the value of each group. It can be understood that the use of laxatives does not affect the intake of other organs SUV max values. In addition, the use of laxatives can really improve the uptake of intestinal SUV values uptake SUV max values significantly decreased (P <0.05). Thus verifiable, laxatives can make use of intestinal SUV value decreased to reduce SUV max value due to the contraction of smooth muscle of the intestinal motility and constipation and intestinal tract caused by increased and improved intestinal qualitative images.

謝辭 i
中文摘要 ii
Abstract iv
圖目錄 ix
表目錄 xi
第一章 緒論
第一節 研究背景與動機 - 1 -
第二節 問題陳述與研究目的 - 2 -
第三節 研究流程 - 3 -
第四節 研究重要性 - 5 -
第二章 文獻探討
第一節 正子斷層掃描 - 6 -
第二節 大腸直腸癌 - 16 -
第三章 研究方法
第一節 研究設計 - 29 -
第二節 研究假說 - 30 -
第三節 材料與方法 - 31 -
第四節 影像判讀與分析 - 34 -
第五節 統計分析方法 - 35 -
第六節 瀉劑的使用(K-P) - 36 -
第四章 結果
第五章 結論與建議
第一節 研究結論 - 57 -
第二節 研究貢獻 - 59 -
第三節 研究限制 - 60 -
參考文獻 - 61 -
中文文獻 - 61 -
英文文獻 - 63 -
附錄
人體委員會通過證明書 - 71 -

中文文獻
朱力行、黃柏凱、關尚勇、黃隸棟(2013)•臨床針對兒童癲癇正子掃描影像診斷之淺介•臨床醫學,71(1),13-20。
姚維仁、白明奇(2010)•F-18 FDDNP 正子掃瞄在阿茲海默氏症的應用•行政院國家科學委員會(編號:NSC99-2623-E006-012-NU)•未出版
黃千芳、賴世偉、劉秋松 (2006)•大腸癌的篩檢•基層醫療,21(7),193-196。
曾嘉慶、李嘉龍、吳啟華(2009)•大腸直腸腫瘤的篩檢與追蹤:文獻回顧與最新指引•內科醫學,20(6),506-513。
國家衛生研究院癌正研究組(1998)•大腸直腸癌診斷與治療之共識。
張祐銓、曾凱元、陸清松、閻紫宸、林武智、陳振宗 (2002)•血管性巴金森癥候群在氟—18—FDG腦部掃描的表現:初步報告•核子醫學雜誌,15(3),P113-117
賴德興 (2003) •大腸直腸癌的認識及預防•聲洋防癌之聲,104,P10-13。
陳德芳(2012)•大腸癌的診斷及治療•台北市醫師公會會刊 56(3 ),41-43。
陳光遠、高潘福 (2013)•FDG PET/CT影像判讀的陷阱:生理性及良性病變
•核子醫學雜誌,26(1),38-47
陳光遠、高潘福(2011)•PET/CT的基礎原理•核子醫學雜誌,24(4),189-
198
衛生福利部國民健康署(2014).100年癌症登記報告.取自
http://www.mohw.gov.tw/cht/DOS/Statistic.aspx?f_list_no=312&fod_list_no=2747
謝銘鈞 (2004)•大腸癌•當代醫學,31(12),953-960。
鄭麗菁(譯)(2008) •醫用解剖學(原作者: RICHARD L. DRAKE)•合記圖書出版社•(2005)•P279-273
英文文獻
Almuhaideb, A., Papathanasiou, N., Bomanji, J. (2011). 18F-FDG PET/CT imaging in oncology. Ann Saudi Med, 31(1),3-13.
Abdel-Nabi, H., Doerr, R. J., Lamonica, D.M., Cronin, V.R., Galantowicz, P.J., Carbone, G.M., Spaulding, M.B.(1998). Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology, 206(3),755–760.
Denecke, T., Rau, B., Hoffmann, K.T., Hildebrandt, B., Ruf, J., Gutberlet, M.,Hunerbein, M., Felix, R., Wust, P., Amthauer, H. (2005). Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: is there a benefit in using functional imaging? Eur Radiol, 15(8),1658–1666.
Engel, H., Steinert, H., Buck, A., Berthold, T., Huch Boni, R. A., Schulthess, G.K. (1996).Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. J Nucl Med ,37,441-446,
Even-Sapir, E., Parag, Y., Lerman, H., Gutman, M., Levine, C., Rabau, M., Figer, A, Metser, U.(2004). Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology,232(3):815–822.
Edge, S.B., Byrd, D.R., Compton, C.C., Fritz, A.G., Greene, F.L., Trotti, A.(2010) AJCC Cancer Staging Manual (Eds.), pp 173-206.
Flamen, P., Stroobants, S., Cutsem, E.V. et al. (1999) Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J Clin Oncol,17,894 –901.
Gregoire, V., Haustermans, K., Geets, X., Roels, S., Lonneux, M. (2007). PET-based treatment planning in radiotherapy: a new standard? J Nucl Med, 48(1),68S–77S.
Greven, K.M., Williams, D.W., McGuirt, W.F. Sr. et al.(2001) Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck, 23:942-6.
Gallagher, B.M., Fowler, J.S., Gutterson, N.I. et al. (1978). Metabolic trapping as a principle of radiopharmaceutical design:some factors responsible for the biodistribution of 18F-2-deoxy-2fluoro-d-glucose, J Nucl Med,19(10),1154-1161.
Higashi, T., Saga, T., Nakamoto, Y., et al. (2002). Relationship between retention index in dual-phase(18)FDG PET, and hexokinase-П and glucose transporter-1 expression in pancreatic cancer. J Nucl Med, 43(2),173-180.
Heriot, A.G., Hicks, R.J., Drummond, E.G., Keck, J., Mackay, J., Chen, F., Kalff, V. (2004). Does positron emission tomography change management in primary rectal cancer? A prospective assessment. Dis Colon Rectum, 47(4):451–458.
Hutchings, M., Loft, A., Hanse, M. et al. (2006). FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma, Blood, 107(1),42-47.
Kim, S.K., Chung, J.K., Kim, B.T. et al. (1999) . Relationship between gastrointestinal F-18-fluorodeoxyglucose accumulation and gastrointestinal symptoms in whole-body PET. Clin Positron Imaging,2,273–279.
Kumar, R., Halanaik, D., Malhotra, A. (2010). Clinical applications of positron emission tomography-computed tomography in oncology. Indian J Cancer. 47,100-19.
Kim, S., Chung, J.K., Kim, B.T. et al.( 1999) . Relationship between gastrointestinal F-18- fluorodeoxyglucose accumulation and gastrointestinal symptoms in whole-body PET. Clin Positron Imaging. 2:273–279.
Larson SM. Cancer or inflammation? A holy grail for nuclear medicine. J Nucl Med 1994;35:1653-5.
Lieberman, D.A., Weiss, D.G., Bond, J.H., Ahnen, D.J., Garewal, H., Chejfec, G. (2000). Use of colonoscopy to screen asymptomatic.adults for colorectal cancer. N Engl J Med, 343: 162-8.
Jadvar H, Schambye RB, Segall GM.(1992). Effect of atropine and sincalide on the interstinal
uptake of 18F-fluorodeoxyglucose. lin Nucl Med,24(12):965-967
Modes of radioactive decay. Cherry, S.R., Sorenson, J. A., Phelps, M.E.ed. (2003).Physics in Nuclesr Medicine.3rded.Chapter4,Saunders,Philadelphia,PA.p.19-30
Mamede, M., Higashi, T., Kitaic, hi. M. et al .(2005). [18F]FDG Uptake and PCNA. Glut-1,and Hexokinase- П Expressions in Cancers and Inflammatory Lesions of the Lung, Neoplasia, 7(4), 369-379.
Mochizuki, T., Tsukamoto, E., Kuge, Y. et al. (2001). FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med,42,1551-5.
McGuirt, W.F., Greven, K., Williams, D. 3 rd. et al. (1998). PET scanning in head and neck oncology:a review. Head Neck, 20(3),208-215.
Mikhaseel, N. G., Hutchings, M., Fields, P.A. et al. (2005). FDG-PET after two to three cycles of chemotherapy predicts progression-free and ovrall survival in high-grade non-Hodgdin lymphoma. Annals of Oncology, 16(9),1514-1523.

Murphy, R., Doerger, K.M., Nathan, M.A., Lowe, V.J. (2009). Pretreatment with diphenoxylate hydrochloride/atropine sulfate (Lomotil) does not decrease physiologic bowel FDG activity on PET/CT scans of the abdomen and pelvis. Mol Imaging Biol, 11,114–117.
Miller, T.R., Grigsby, P.W. (2002). Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys, 53(2),353–359.
Mah, K., Caldwell, C.B., Ung, Y.C., Danjoux, C.E., Balogh, J.M., Ganguli, S.N., Ehrlich, L.E., Tirona, R.(2002). The impact of (18) FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly-defined non-small-cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys, 52(2),339–350.
M.G. van der Vaart, R. Meerwaldt, R.H.J.A. Slart, G.M. van Dam, R.A. Tio4 and C.J. Zeebregts(2008). Application of PET/SPECT Imaging in Vascular Disease. Eur J Vasc Endovasc Surg 35(5), 507-513
Brien, M.J. Colorectal polyp. In: Cohen, A.M., Winawer, S.J. eds. Cancer of the Colon, Rectum, and Anus. New York, NY: McGraw-Hill; (1995):127–135.
Peng, J., He,Y., Xu, J.et al. (2011). Detection of incidental colorectal tumours with 18F labelled 2 fluoro 2 deoxyglucose positron emission tomography/computed tomography scans: results of a prospective study. Colorectal Dis, 13, e374 e378,.
Rose, P.G., Adler, L.P., Rodriguez, M. et al. (1999). Positron emission tomography for evaluating para-aortic nodal metastisis in locally advanced cervical cancer before surgical staging:a sugicopathologic study. J Clin Oncol, 17(1),41-45
Stahl, A., Weber, W.A., Avril, N., Schwaiger, M. (2000). Effect of N-butylscopolamine on intestinal uptake of fluorine-18-fluorodeoxyglucose in PET imaging of the abdomen. Nuklearmedizin, 39,241–245.
Selby, J.V., Friedman, G.D., Quesenberry, C.P. Jr., Weiss, N.S.(1992). A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med, 326:653– 657.
Strauss, L.G. and Conti, P.S .(1991). The applications of FDG PET in clinical oncology. J Nucl Med, 32(4),623-648.
Sugawara, Y., Eisbruch, A., Kosuda, S. et al. (1999). Evaluation of FDG PET patients with cervical cancer. J Nucl Med, 40(7),1125-1131.
Winawer, S.J., Stewart, E.T., Zauber, A.G., AJohnson, C.D., Chen, M.H., Toledano, A.Y. et al. (2008 ).Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med, 359, 1207-17. comparisonof colonoscopy and double-contrast barium enema forsurveillance after polypectomy. N Engl J Med (2000), 342:1766-72.
Weston, B.R., Iyer, R.B., Qiao, W., Lee, J.H., Bresalier, R.S., Ross, W.A. (2010) Ability of integrated positron emission and computed tomography to detect significant colonic pathology: the expe¬rience of a tertiary cancer center. Cancer, 116, 1454 1461.
Warburg, O. (1931).The metabolism of tumors.New York. NY:Smith,129-169.
Winawer, S.J., Stewart, E.T., Zauber, A.G. et al.(2000). A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. N Engl J Med, 342,1766 –1772.
Yen, T.C., See, L.C., Chang, T.C. et al. (2004). Defining the priority of using 18F-FDG PET for recurrent cervical cancer. J Nucl Med, 45(10),1632-1639
Yen, T.C., See, L.C., Lai, C.H. et al.(2004). Defining the priority of using 18F-FDG PET for recurrent cervical cancer. J Nucl Med, 45(1),22-29
Younes, M., Brown, R.W., Stephenson, M., Gondo, M., & Cagle, P.T.(1997). Over expression of Glut1 and Glut3 in stage I non-small cell lung carcionoma is associated with poor survival. Cancer, 80 (6),1046-1051.
Yasuda, S., Ide, M., Takagi, S., Shohtsu, A. (1998) .F-18 FDG uptake in colonic adenoma. Clin Nucl Med, 23,99 –100.
Yamamoto, F., Nakada, K., Zhao, S., Satoh, M., Asaka, M., Tamaki, N. (2004). Gastrointestinal uptake of FDG after N-butylscopolamine or omeprazole treatment in the rat. Ann Nucl Med, 18,637–640.
Yasuda, S., Takahashi, W., Takagi, S., Fujii, H., Ide, M., Shohtsu, A. (1998) .Factors influencing physiological FDG uptake in the intestine. Tokai J Exp Clin Med, 23:241–244.
Van der Vaart, M.G., Meerwaldt, R., Slart, R.H., van Dam, G.M., Tio, R.A., Zeebregts C.J.(2008), Application of PET/SPECT imaging in vascular disease.,Eur J Vasc Endovasc Surg, 35(5), P507-13

QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
系統版面圖檔 系統版面圖檔